arrow
J

Jacopo Canzian

IRCCS Humanitas Research Hospital
H指数:3
被引数:50

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Drugging the luminal axis end to end: a review of next-generation endocrine and targeted therapies in HR+/HER2- metastatic breast cancer.

靶向管腔轴:HR+/HER2-转移性乳腺癌下一代内分泌和靶向疗法的综述

2026-10-230
OAAI
Trastuzumab deruxtecan in HER2-positive metastatic breast cancer with severe hepatic dysfunction: a case report and narrative literature review

曲妥珠单抗德鲁替康在HER2阳性转移性乳腺癌合并严重肝功能不全中的应用:病例报告及文献综述

2026-09-140
OA
“Neoadjuvant Trastuzumab Deruxtecan for High-Risk HER2-Positive Early Breast Cancer: Does the Evidence Support Its Use as a New Standard-of-Care?”

新辅助治疗中曲妥珠单抗德鲁替康用于高危HER2阳性早期乳腺癌:现有证据是否支持其作为新的标准治疗方案?

2026-05-140
PRE
[18F]FDG PET/CT as a biomarker for response evaluation in neoadjuvant treatment of early breast cancer: could it become a game-changer in the scenario of the emerging (de)-escalation strategies?

^{18}F-FDG PET/CT作为早期乳腺癌新辅助治疗中评估疗效的生物标志物:在新兴的增减量策略背景下,它能否成为变革性因素?

2025-12-010
OAAI
From intravenous to subcutaneous pertuzumab/trastuzumab in breast cancer: Clinical and pharmacoeconomic drivers and barriers to switching

从静脉到皮下注射帕妥珠单抗/曲妥珠单抗治疗乳腺癌:转换的临床和药物经济学驱动因素与障碍

2025-12-010
PRE
Heterogeneity of progression-free survival surrogacy by sex in randomized trials testing immunotherapy in non-small cell lung cancer

非小细胞肺癌免疫治疗随机试验中,按性别划分的无进展生存期代理终点异质性

2025-10-010
OAAI
Incorporating radiomic MRI models for presurgical response assessment in patients with early breast cancer undergoing neoadjuvant systemic therapy: Collaborative insights from breast oncologists and radiologists

纳入放射组学MRI模型用于早期乳腺癌患者新辅助系统性治疗前手术前反应评估:乳腺肿瘤学家和放射科医师的协作见解

2025-06-010
PRE
Outcomes of patients with advanced solid tumors who discontinued immune-checkpoint inhibitors: a systematic review and meta-analysis

停用免疫检查点抑制剂的晚期实体瘤患者的结局: 系统回顾和荟萃分析

2024-07-010
OAAI